| Description |
Edaglitazone is a potent, selective and orally active PPARγ agonist, with EC50s of 35.6 nM and 1053 nM for PPARα and PPARγ, respectively. Edaglitazone displays antiplatelet, antidiabetic and anti-hyperglycemic activity[1][2][3].
|
| Related Catalog |
|
| Target |
PPARγ:35.6 nM (EC50)
PPARα:1053 nM (EC50)
|
| In Vitro |
Edaglitazone (3-16 μM; 5 min) inhibits the collagen (1.2 μg/mL)-induced platelet aggregation. Edaglitazone increases the intraplatelet levels of cAMP in a concentration dependent manner. Edaglitazone preventes the Collagen-induced intraplatelet levels of PPARγ decrease[3].
|
| In Vivo |
Edaglitazone (4.4 mg/kg; p.o. daily for 10 days) enhances insulin sensitivity in obese rats[2].
|
| References |
[1]. Dietz M, et, al. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem. 2012 Jun;7(6):1101-11. [2]. Fürnsinn C, et, al. Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism. Br J Pharmacol. 1999 Nov;128(6):1141-8. [3]. Muñoz-Gutiérrez C, et, al. Study of the interactions between Edaglitazone and Ciglitazone with PPARγ and their antiplatelet profile. Life Sci. 2017 Oct 1;186:59-65.
|
